DEVON PRICE: Open Payments
NPI 1336731124 · KELLER, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$701 in 41 payments from 11 companies in 2025. Trend: 2023 $1,529 · 2024 $1,195 · 2025 $701
Food & beverage: $701
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $184 |
| Novo Nordisk Inc | 6 | $108 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $102 |
| Lilly USA, LLC | 5 | $88 |
| Otsuka America Pharmaceutical, Inc. | 3 | $55 |
| PFIZER INC. | 2 | $38 |
| AstraZeneca Pharmaceuticals LP | 2 | $35 |
| Dexcom, Inc. | 2 | $29 |
| Amgen Inc. | 2 | $28 |
| Astellas Pharma US Inc | 1 | $21 |
Products named: VRAYLAR, CAPLYTA, MOUNJARO, Ozempic, REXULTI, QULIPTA, Wegovy, Dexcom G6 Transmitter.
Industry payments across TX — which companies pay providers there.
